Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial

BACKGROUND: COVID-19 is associated with a prothrombotic state. Current guidelines recommend prophylactic anticoagulation upon hospitalization. METHODS: COVID-PREVENT, an open-label, multicenter, randomized, clinical trial enrolled patients (≥ 18 years) with moderate to severe COVID-19 and age-adjust...

Descripción completa

Detalles Bibliográficos
Autores principales: Rauch-Kröhnert, Ursula, Puccini, Marianna, Placzek, Marius, Beyer-Westendorf, Jan, Jakobs, Kai, Friebel, Julian, Hein, Selina, Seidel, Mirko, Pieske, Burkert, Massberg, Steffen, Witzenrath, Martin, Zeiher, Andreas, Friede, Tim, Anker, Stefan D., Landmesser, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584737/
https://www.ncbi.nlm.nih.gov/pubmed/37407731
http://dx.doi.org/10.1007/s00392-023-02240-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584737/
https://www.ncbi.nlm.nih.gov/pubmed/37407731
http://dx.doi.org/10.1007/s00392-023-02240-1

Ejemplares similares